| Name | Folkestone |
|---|---|
| Location | 100 Promenade Avenue, Wayzata, Minnesota |
| Certified By | Medicare |
| No. of Certified Beds | 30 |
| Occupancy Rate | 80.33% |
| Medicare ID (CCN) | 245621 |
| Legal Business Name | Wayzata Bay Senior Housing Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1386083160 |
| Organization Name | WAYZATA BAY SENIOR HOUSING, INC. |
| Doing Business As | FOLKESTONE |
| Address | 100 Promenade Ave, Wayzata, MN 55391 |
| Phone Number | 651-631-6120 |
News Archive
Losing weight could prevent or even reverse diabetes, according to late breaking research presented today at ESC Congress 2020.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.
Though the Academy of Pediatrics advises against the consumption of energy drinks by teens, researchers at Dartmouth's Norris Cotton Cancer Center found that manufacturers market the bulk of their products on television channels that likely appeal to teen audiences.
Scientists and physicians at University of California San Diego School of Medicine, working with colleagues at the U.S. Navy Medical Research Center - Biological Defense Research Directorate, Texas A&M University, a San Diego-based biotech and elsewhere, have successfully used an experimental therapy involving bacteriophages - viruses that target and consume specific strains of bacteria - to treat a patient near death from a multidrug-resistant bacterium.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Losing weight could prevent or even reverse diabetes, according to late breaking research presented today at ESC Congress 2020.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.
Though the Academy of Pediatrics advises against the consumption of energy drinks by teens, researchers at Dartmouth's Norris Cotton Cancer Center found that manufacturers market the bulk of their products on television channels that likely appeal to teen audiences.
Scientists and physicians at University of California San Diego School of Medicine, working with colleagues at the U.S. Navy Medical Research Center - Biological Defense Research Directorate, Texas A&M University, a San Diego-based biotech and elsewhere, have successfully used an experimental therapy involving bacteriophages - viruses that target and consume specific strains of bacteria - to treat a patient near death from a multidrug-resistant bacterium.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.49 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.26 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.6 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.33 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.1 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 10.2 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 89.8 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 26.53 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 89.61 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.38 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.84 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.11 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.66 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 63.22 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 80.83 | 82.93 |
News Archive
Losing weight could prevent or even reverse diabetes, according to late breaking research presented today at ESC Congress 2020.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.
Though the Academy of Pediatrics advises against the consumption of energy drinks by teens, researchers at Dartmouth's Norris Cotton Cancer Center found that manufacturers market the bulk of their products on television channels that likely appeal to teen audiences.
Scientists and physicians at University of California San Diego School of Medicine, working with colleagues at the U.S. Navy Medical Research Center - Biological Defense Research Directorate, Texas A&M University, a San Diego-based biotech and elsewhere, have successfully used an experimental therapy involving bacteriophages - viruses that target and consume specific strains of bacteria - to treat a patient near death from a multidrug-resistant bacterium.
› Verified 7 days ago